arrow
K

Kazumasa Komura

Kawasaki Medical School
H指数:25
被引数:2,354

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author's reply to 'Bayesian interpretation of febrile neutropenia risk and primary G-CSF prophylaxis during darolutamide triplet therapy'

作者回复:“达罗鲁胺三联疗法期间发热性中性粒细胞减少症风险和初级G-CSF预防的贝叶斯解释”

2026-08-010
PRE
Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium

去势敏感型前列腺癌患者接受雄激素受体信号抑制剂治疗后肺转移的预后影响: 来自超日本财团的数据

2025-10-010
PRE
Deciphering RCC immunotherapy outcomes: insights from a Japanese multi-institutional study on the CANLPH score's impact

解读RCC免疫治疗效果:日本多机构研究关于CANLPH评分影响的见解

2025-02-241
PRE
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium

体重指数与接受恩诺单抗维多汀治疗的转移性尿路上皮癌患者肿瘤反应的相关性:ULTRA-Japan联盟的数据

2025-01-311
PRE
Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma
2024-09-170
OAAI
Oncologic Outcomes of Patients with Early-Stage Cervical Cancer after Minimally Invasive Radical Hysterectomy and Sentinel Lymph Node Biopsy

微创根治性子宫切除术和前哨淋巴结活检对早期宫颈癌患者肿瘤学预后的影响

2024-07-080
OAAI
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
2024-05-285
PRE
Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience
2024-05-060
OAAI
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
2024-03-285
PRE
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
2023-11-1811
OAAI
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma

pembrolizumab治疗铂难治性尿路上皮癌后的重新挑战化疗

2022-09-269
PRE